Omega Therapeutics logo

Omega TherapeuticsNASDAQ: OMGA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 July 2021

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$44.88 M
-95%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector
-45%vs. 3y high
75%vs. sector
-99%vs. 3y high
64%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:50:49 GMT
$0.81$0.00(0.00%)

Dividend

No data over the past 3 years
$2.61 M$1.20 M
$2.61 M-$16.44 M

Analysts recommendations

Institutional Ownership

OMGA Latest News

Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property
accesswire.com19 November 2024 Sentiment: POSITIVE

VANCOUVER, BC / ACCESSWIRE / November 19, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce results from its field work program at its Lekcin Property, located 120 km east of Vancouver. Background The Lekcin Property (or the "Property") consists of six Mineral Titles Online (MTO) claims that are under option to the Company.

Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com14 November 2024 Sentiment: POSITIVE

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.40 per share a year ago.

Omega Pacific Earns 51% Interest in Williams Property
accesswire.com12 November 2024 Sentiment: POSITIVE

VANCOUVER, BC / ACCESSWIRE / November 12, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce the Company is exercising its option to acquire a 51% interest in the Williams Property (the "Property") from Copaur Minerals inc. On February 29, 2024 the Company entered into an option agreement (the "Agreement") with CopAur Minerals Inc ("CopAur") to acquire up to a 100% interest in the Property, in several stages.

Omega Pacific Adds John Williamson as Independent Director
accesswire.com05 November 2024 Sentiment: POSITIVE

VANCOUVER, BC / ACCESSWIRE / November 5, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to welcome Mr. John Williamson, P.Geol.

Omega Pacific Extends Historical Hole WM22-02 Mineralization to 2.16 G/t Au Over 96.92 Metres
accesswire.com28 October 2024 Sentiment: POSITIVE

VANCOUVER, BC / ACCESSWIRE / October 28, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce additional assay results from its 2024 drill program at the Williams Property in British Columbia's Golden Horseshoe. Drill Hole WM22-02-extension ("ext") significantly extended mineralization and continued the strong intervals from the property's previous campaign (Figure 1).

Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
globenewswire.com15 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings.

Omega Pacific Issues Common Shares for Three Additional Claims in the Golden Horseshoe Area in British Columbia
accesswire.com18 September 2024 Sentiment: POSITIVE

VANCOUVER, BC / ACCESSWIRE / September 18, 2024 / Omega Pacific Resources Inc. (CSE:OMGA) ("Omega" or the "Company") announces that further to its news release dated May 24, 2024, the Company has issued 71,500 common shares to Steven Scott for three mineral exploration claims located in the Golden Horseshoe Area in British Columbia covering 51.716 hectares pursuant to an asset purchase agreement dated May 22, 2024 and amended on September 13, 2024. These common shares were issued on September 18, 2024 and are subject to the statutory four month and one date hold period, which expires on January 19, 2025.

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
globenewswire.com17 September 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega's approach to precision epigenomic control and the ability of OTX-2002 to controllably regulate the historically undruggable MYC gene in multiple models of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

Omega Pacific Intersects Three Separate Gold Zones Demonstrating Bulk-Tonnage Gold Mineralization at its Williams Property
accesswire.com08 August 2024 Sentiment: POSITIVE

VANCOUVER, BC / ACCESSWIRE / August 8, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce additional drill results from its 2024 drill program at the Williams Property in British Columbia's Golden Horseshoe. Assay results from Phase One's second drill hole (WM24-02) continue to demonstrate high-grade and bulk tonnage mineralization (Figure 1).

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

  • 1(current)
  • 2

What type of business is Omega Therapeutics?

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

What sector is Omega Therapeutics in?

Omega Therapeutics is in the Healthcare sector

What industry is Omega Therapeutics in?

Omega Therapeutics is in the Biotechnology industry

What country is Omega Therapeutics from?

Omega Therapeutics is headquartered in United States

When did Omega Therapeutics go public?

Omega Therapeutics initial public offering (IPO) was on 30 July 2021

What is Omega Therapeutics website?

https://omegatherapeutics.com

Is Omega Therapeutics in the S&P 500?

No, Omega Therapeutics is not included in the S&P 500 index

Is Omega Therapeutics in the NASDAQ 100?

No, Omega Therapeutics is not included in the NASDAQ 100 index

Is Omega Therapeutics in the Dow Jones?

No, Omega Therapeutics is not included in the Dow Jones index

When was Omega Therapeutics the previous earnings report?

No data

When does Omega Therapeutics earnings report?

The next expected earnings date for Omega Therapeutics is 28 March 2025